Maravai Life Sciences downgraded by Robert W. Baird with a new price target

2/26/25 7:15:06 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Robert W. Baird downgraded Maravai Life Sciences from Outperform to Neutral and set a new price target of $3.00 from $9.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MRVI

Date	Price Target	Rating	Analyst
2/26/2025	$9.00 → $3.00	Outperform → Neutral	Robert W. Baird
12/19/2024		Neutral	Guggenheim
12/5/2024	$4.25	Neutral → Sell	Goldman
11/14/2024		Peer Perform	Wolfe Research
11/8/2024		Outperform → Mkt Perform	William Blair
8/28/2024	$10.00	Overweight	Wells Fargo
8/13/2024	$11.00 → $10.00	Overweight → Equal-Weight	Morgan Stanley
4/10/2024	$15.00	Buy	Craig Hallum